Literature DB >> 23050043

The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Aashi Chaturvedi1, Laura M Hoffman, Alana L Welm, Stephen L Lessnick, Mary C Beckerle.   

Abstract

Ewing sarcoma is a tumor of the bone and soft tissue caused by the expression of a translocation-derived oncogenic transcription factor, EWS/FLI. Overt metastases are associated with a poor prognosis in Ewing sarcoma, but patients without overt metastases frequently harbor micrometastatic disease at presentation. This suggests that the metastatic potential of Ewing sarcoma exists at an early stage during tumor development. We have therefore explored whether the inciting oncogenic event in Ewing sarcoma, EWS/FLI, directly modulates tumor cell features that support metastasis, such as cell adhesion, cell migration, and cytoarchitecture. We used an RNAi-based approach in patient-derived Ewing sarcoma cell lines. Although we hypothesized that EWS/FLI might induce classic metastatic features, such as increased cell adhesion, migration, and invasion (similar to the phenotypes observed when epithelial malignancies undergo an epithelial-to-mesenchymal transition during the process of metastasis), surprisingly, we found the opposite. Thus, EWS/FLI expression inhibited the adhesion of isolated cells in culture and prevented adhesion in an in vivo mouse lung assay. Cell migration was similarly inhibited by EWS/FLI expression. Furthermore, EWS/FLI expression caused a striking loss of organized actin stress fibers and focal adhesions and a concomitant loss of cell spreading, suggesting that EWS/FLI disrupts the mesenchymal phenotype of a putative tumor cell-of-origin. These data suggest a new paradigm for the dissemination and metastasis of mesenchymally derived tumors: these tumors may disseminate via a "passive/stochastic" model rather than via an "active" epithelial-to-mesenchymal type transition. In the case of Ewing sarcoma, it appears that the loss of cell adhesion needed to promote tumor cell dissemination might be induced by the EWS/FLI oncogene itself rather than via an accumulation of stepwise mutations.

Entities:  

Keywords:  EWS/FLI; Ewing sarcoma; cell adhesion; cytoskeleton; metastasis

Year:  2012        PMID: 23050043      PMCID: PMC3463921          DOI: 10.1177/1947601912457024

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  66 in total

1.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

Authors:  Richard Smith; Leah A Owen; Deborah J Trem; Jenny S Wong; Jennifer S Whangbo; Todd R Golub; Stephen L Lessnick
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 3.  Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.

Authors:  Leah A Owen; Stephen L Lessnick
Journal:  Cell Cycle       Date:  2006-09-15       Impact factor: 4.534

Review 4.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

5.  Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.

Authors:  Oscar M Tirado; Silvia Mateo-Lozano; Joaquín Villar; Luis E Dettin; Anna Llort; Soledad Gallego; Jozef Ban; Heinrich Kovar; Vicente Notario
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

Review 6.  Context matters: the hen or egg problem in Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Semin Cancer Biol       Date:  2005-06       Impact factor: 15.707

Review 7.  Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Semin Cancer Biol       Date:  2010-12-09       Impact factor: 15.707

8.  The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells.

Authors:  Valérie Amsellem; Marie-Hélène Kryszke; Martial Hervy; Frédéric Subra; Rafika Athman; Hervé Leh; Corinne Brachet-Ducos; Christian Auclair
Journal:  Exp Cell Res       Date:  2004-12-13       Impact factor: 3.905

Review 9.  Integrin signalling during tumour progression.

Authors:  Wenjun Guo; Filippo G Giancotti
Journal:  Nat Rev Mol Cell Biol       Date:  2004-10       Impact factor: 94.444

10.  Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility, and deficits in actin remodeling.

Authors:  Laura M Hoffman; Christopher C Jensen; Susanne Kloeker; C-L Albert Wang; Masaaki Yoshigi; Mary C Beckerle
Journal:  J Cell Biol       Date:  2006-02-27       Impact factor: 10.539

View more
  42 in total

1.  Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.

Authors:  Laurie K Svoboda; Ashley Harris; Natashay J Bailey; Raphaela Schwentner; Eleni Tomazou; Cornelia von Levetzow; Brian Magnuson; Mats Ljungman; Heinrich Kovar; Elizabeth R Lawlor
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

2.  [The role of focal adhesions in Ewing's sarcoma].

Authors:  K Steinestel; T G P Grünewald; W Hartmann
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 3.  [Functional genomics of Ewing sarcoma].

Authors:  T G P Grünewald
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.

Authors:  Sun Choo; Ping Wang; Robert Newbury; William Roberts; Jing Yang
Journal:  Pediatr Blood Cancer       Date:  2017-09-05       Impact factor: 3.167

5.  Wnt/β-catenin-activated Ewing sarcoma cells promote the angiogenic switch.

Authors:  Allegra G Hawkins; Elisabeth A Pedersen; Sydney Treichel; Kelsey Temprine; Colin Sperring; Jay A Read; Brian Magnuson; Rashmi Chugh; Elizabeth R Lawlor
Journal:  JCI Insight       Date:  2020-07-09

6.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.

Authors:  Elizabeth T Wiles; Russell Bell; Dafydd Thomas; Mary Beckerle; Stephen L Lessnick
Journal:  Genes Cancer       Date:  2013-11

7.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

8.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

9.  Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Authors:  Savita Sankar; Emily R Theisen; Jared Bearss; Timothy Mulvihill; Laura M Hoffman; Venkataswamy Sorna; Mary C Beckerle; Sunil Sharma; Stephen L Lessnick
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

10.  Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.

Authors:  Elisabeth A Pedersen; Rajasree Menon; Kelly M Bailey; Dafydd G Thomas; Raelene A Van Noord; Jenny Tran; Hongwei Wang; Ping Ping Qu; Antje Hoering; Eric R Fearon; Rashmi Chugh; Elizabeth R Lawlor
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.